Pharmaceuticals & Medical Devices Bureau of India partnered with cooperative sector to open Jan Aushadhi Kendras through PACS

Till 30th November 2024, more than 2690 PACS have been given initial approval and 687 Kendras have been opened in PACS

Aster DM Healthcare launches precision oncology, offering data-driven, personalized cancer care

Harnessing advanced data analysis for early detection, prevention and better outcomes

Acoramidis receives positive CHMP opinion for treatment of transthyretin amyloid cardiomyopathy

Final decision from the European Commission is anticipated within the coming months

Lynparza demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase 3 trial

First and only PARP inhibitor to improve overall survival in early breast cancer

Biocon Biologics recognized as Asia IP Elite for 2024 by IAM

Biocon Biologics is among the two pharmaceutical companies from India in the 93 companies featuring on the Asia IP Elite 2024 list

Arvinas and Pfizer presents phase 1b data from the TACTIVE-U sub-study of Vepdegestrant in combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium

Vepdegestrant in combination with abemaciclib demonstrated encouraging clinical activity (clinical benefit rate

Ichnos Glenmark Innovation presents first clinical data from Phase 1 study of Trispecific TREAT antibody

Showing High Overall Response Rate (ORR) with durable responses and favorable safety profile in patients with heavily pretreated multiple myeloma

Lupin receives tentative approval from USFDA for Abacavir, Dolutegravir and Lamivudine tablets for oral suspension

The fixed-dose combination of Abacavir 60 mg/Dolutegravir 5 mg/Lamivudine 30 mg tablets for oral suspension is a once-daily single-pill regimen

Laurus Labs invests in Laurus Bio

Metropolis Healthcare acquires Core Diagnostics for Rs. 246.8 Cr

Aims to become India’s leading cancer testing company